15 recruiting, 4 terminated, 2 active not recruiting, 2 completed. 16 Phase 1, 8 Phase 2, 1 Not applicable, 1 Phase 3.
Follow Diffuse Midline Glioma, H3 K27M-Mutant: new trials by email Literature Review of Diffuse Midline Glioma, H3 K27M-Mutant trials Research Report on Diffuse Midline Glioma, H3 K27M-Mutant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG) ADI-PEG 20 (Arginine deiminase pegylated), Temozolomide (TMZ), Standard of Care Radiation Therapy (RT) - Glioblastoma, High-Grade Glioma (WHO III-IV) | Phase 1 / Phase 2 | Not yet recruiting | Sabine Mueller, MD, PhD | 97 | 2027-06-01 | 2026-09-15 |
| A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors NEO100 - Pediatric Tumor of CNS, Pediatric Tumor of Brain | Phase 1 | Recruiting | Neonc Technologies, Inc. | 12 | 2026-09-08 | 2026-09-15 |
| Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma/Diffuse Midline Glioma and Response to Treatment (Regardless of Mutation Status) S-Gboxin - Glioblastoma Multiforme, Diffuse Midline Glioma, H3 K27M-Mutant | Phase 1 | Suspended | Petrov, Andrey | 10 | 2026-05-20 | 2026-06-03 |
| A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Diffuse Intrinsic Pontine Glioma VRT106 for injection - Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma | Phase 2 | Recruiting | Guangzhou Virotech Pharmaceutical Co., Ltd. | 10 | 2026-05-07 | 2026-10-30 |
| Atovaquone Combined With Radiation in Children With Malignant Brain Tumors Atovaquone, Radiation Therapy - High-grade Glioma, Medulloblastoma | Phase 1 | Recruiting | Emory University | 18 | 2025-03-28 | 2026-08-03 |
| Study of Olutasidenib and Temozolomide in HGG Olutasidenib + TMZ - High Grade Glioma, Astrocytoma | Phase 2 | Recruiting | Rigel Pharmaceuticals | 60 | 2025-02-01 | 2026-09-01 |
| Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant Ribociclib, Everolimus, Temozolomide (TMZ) - High Grade Glioma, Diffuse Intrinsic Pontine Glioma | Phase 2 | Recruiting | Nationwide Children's Hospital | 120 | 2024-08-22 | 2026-05-29 |
| Targeted Pediatric High-Grade Glioma Therapy High Grade Glioma, Diffuse Intrinsic Pontine Glioma | Recruiting | Nationwide Children's Hospital | 350 | 2024-08-02 | 2026-09-08 | |
| CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults Treatment with CD200AR-L - Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent High Grade Glioma | Phase 1 | Recruiting | OX2 Therapeutics | 24 | 2024-03-15 | 2024-03-12 |
| RE-irradiation of Diffuse MIdline Glioma paTients Re-irradiation - Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma | Not applicable | Not yet recruiting | Copenhagen University Hospital, Rigshospitalet | 59 | 2023-10-01 | 2023-10-23 |
| CAR T Cells to Target GD2 for DMG GD2 CAR T cells - Diffuse Midline Glioma, H3 K27M-Mutant | Phase 1 | Recruiting | University College, London | 12 | 2023-08-15 | 2026-08-11 |
| Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma Cyclophosphamide, Fludarabine, Autologous Anti-H3.3K27M TCR-expressing T-cells - Diffuse Midline Glioma, H3 K27M-Mutant | Phase 1 | Terminated | University of California, San Francisco | 4 | 2023-07-20 | 2026-07-13 |
| FUS Etoposide for DMG Etoposide; Oral, 50 Mg, Focused ultrasound with neuro-navigator-controlled sonication - Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant | Phase 1 | Recruiting | Columbia University | 10 | 2023-06-05 | 2026-01-28 |
| Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors B7-H3-CAR T cells - Central Nervous System Neoplasms, Atypical Teratoid/Rhabdoid Tumor | Phase 1 | Active not recruiting | St. Jude Children's Research Hospital | 29 | 2023-04-27 | 2026-07-06 |
| Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification Observational - Glioma, Glioneuronal Tumor | Recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 1650 | 2023-03-21 | 2025-12-17 | |
| Oral AMXT 1501 Dicaprate in Combination With IV DFMO AMXT1501, DFMO - Cancer, Solid Tumor | Phase 1 / Phase 2 | Terminated | Aminex Therapeutics, Inc. | 15 | 2022-11-29 | 2024-12-24 |
| Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0 Everolimus, ONC201, Radiotherapy - Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant | Phase 3 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 433 | 2022-09-29 | 2026-10-21 |
| rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG rHSC-DIPGVax, Balstilimab, Zalifrelimab - Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant | Phase 1 | Recruiting | Ann & Robert H Lurie Children's Hospital of Chicago | 36 | 2022-01-10 | 2026-03-17 |
| Combination Therapy for the Treatment of Diffuse Midline Gliomas ONC201, Radiation Therapy, Paxalisib - Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant | Phase 2 | Recruiting | University of California, San Francisco | 360 | 2021-10-20 | 2026-06-26 |
| Stereotactic Biopsy Split-Course Radiation Therapy in Diffuse Midline Glioma, SPORT-DMG Trial Hypofractionated Radiation Therapy, Questionnaire Administration, Magnetic Resonance Imaging - Diffuse Midline Glioma, H3 K27M-Mutant | Phase 2 | Active not recruiting | Mayo Clinic | 17 | 2021-10-11 | 2026-09-18 |
Showing 20 of 27. Sign in to see all of them.
Diffuse Intrinsic Pontine Glioma (17) · Glioma (15) · Glioblastoma (8) · Brain Neoplasms (6) · Astrocytoma (5) · Central Nervous System Neoplasms (4) · Ependymoma (3) · Gliosarcoma (3) · Medulloblastoma (3) · Pinealoma (3) · Choroid Plexus Neoplasms (2) · Oligodendroglioma (2) · Spinal Cord Neoplasms (2) · Brain Diseases (1) · Brain Stem Neoplasms (1)
Neoplasms by Histologic Type (24) · Neoplasms, Glandular and Epithelial (24) · Neoplasms, Nerve Tissue (24) · Neoplasms (23) · Neoplasms, Germ Cell and Embryonal (23) · Neoplasms, Neuroepithelial (23) · Neuroectodermal Tumors (23) · Neoplasms by Site (21) · Nervous System Diseases (21) · Central Nervous System Diseases (20) · Nervous System Neoplasms (20) · Brain Diseases (19) · Central Nervous System Neoplasms (17) · Infratentorial Neoplasms (17) · Brain Stem Neoplasms (16)
Radiotherapy (4) · Radiation (3) · Temozolomide (3) · Everolimus (2) · TIC10 compound (2) · ADI PEG20 (1) · Atovaquone (1) · Cyclophosphamide (1) · Drug Tolerance (1) · Etoposide (1) · GDC-0084 (1) · Imiquimod (1) · Immune Checkpoint Inhibitors (1) · Injections (1) · Ipilimumab (1)
Columbia University (2) · Nationwide Children's Hospital (2) · Sabine Mueller, MD, PhD (2) · University of California, San Francisco (2) · Aminex Therapeutics, Inc. (1) · Ann & Robert H Lurie Children's Hospital of Chicago (1) · Bexion Pharmaceuticals, Inc. (1) · Children's Hospital Medical Center, Cincinnati (1) · Copenhagen University Hospital, Rigshospitalet (1) · Emory University (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Guangzhou Virotech Pharmaceutical Co., Ltd. (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Jazz Pharmaceuticals (1) · Mayo Clinic (1)
United States (21) · Australia (5) · United Kingdom (5) · Canada (4) · Germany (4) · Netherlands (4) · New Zealand (4) · Switzerland (3) · Belgium (2) · France (2) · Greece (2) · Norway (2) · Spain (2) · Austria (1) · China (1)
Maryam Fouladi, MD (3) · Hideho Okada, MD, PhD (2) · Margot Lazow, MD (2) · Sabine Mueller, MD, PhD (2) · Sabine Mueller, MD, PhD, MAS (2) · Ashley Plant-Fox, MD (1) · Cheng-Chia Wu, MD, PhD (1) · Christopher DeRenzo, MD (1) · Giedre Krenciute, PhD (1) · Josh Neman, PhD (1) · Kelsey Bertrand, MD, MSc (1) · Lindsey Hoffman, DO (1) · Maja V Maraldo (1) · Michael Armstrong, MD (1)
PMID 32817593, PMID 35157764, PMID 35417530, PMID 37195023, PMID 39626445
2014 (1), 2023 (1), R01NS124607 (1), UM1CA097452 (1)